Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed the day trading at $3.08 up 1.32% from the previous closing price of $3.04. In other words, the price has increased by $+0.0400 from its previous closing price. On the day, 2357609 shares were traded.
Ratios:
For a better understanding of XERS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.38 and its Current Ratio is at 1.82. In the meantime, Its Debt-to-Equity ratio is 58.90 whereas as Long-Term Debt/Eq ratio is at 58.29.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 28, 2023, initiated with a Buy rating and assigned the stock a target price of $4.50.
On October 21, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $4.
On April 28, 2022, Craig Hallum started tracking the stock assigning a Buy rating and target price of $6.50.Craig Hallum initiated its Buy rating on April 28, 2022, with a $6.50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 27 when SHERMAN JEFFREY W bought 5,400 shares for $1.87 per share. The transaction valued at 10,098 led to the insider holds 5,400 shares of the business.
Pieper Steven bought 28,000 shares of XERS for $54,600 on Nov 20. The insider now owns 1,176,912 shares after completing the transaction at $1.95 per share. On Nov 20, another insider, HALKUFF DAWN, who serves as the Director of the company, bought 5,410 shares for $1.84 each. As a result, the insider paid 9,954 and bolstered with 5,410 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 424.04M and an Enterprise Value of 586.01M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.79 while its Price-to-Book (P/B) ratio in mrq is 110.04. Its current Enterprise Value per Revenue stands at 3.84 whereas that against EBITDA is -23.86.
Stock Price History:
Over the past 52 weeks, XERS has reached a high of $3.26, while it has fallen to a 52-week low of $1.13. The 50-Day Moving Average of the stock is 2.6556, while the 200-Day Moving Average is calculated to be 2.3201.
Shares Statistics:
Over the past 3-months, XERS traded about 2.13M shares per day on average, while over the past 10 days, XERS traded about 2.15M shares per day. A total of 136.27M shares are outstanding, with a floating share count of 123.47M. Insiders hold about 10.61% of the company’s shares, while institutions hold 41.91% stake in the company. Shares short for XERS as of Feb 15, 2024 were 9.42M with a Short Ratio of 4.42, compared to 10.41M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.82% and a Short% of Float of 6.97%.
Earnings Estimates
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.13, while EPS last year was -$0.1. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.07 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.36 and -$0.48 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.27, with 5 analysts recommending between -$0.13 and -$0.38.
Revenue Estimates
4 analysts predict $43.55M in revenue for the current quarter. It ranges from a high estimate of $45.5M to a low estimate of $42.02M. As of the current estimate, Xeris Biopharma Holdings Inc’s year-ago sales were $33.14M, an estimated increase of 31.40% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $43.07M, an increase of 29.70% less than the figure of $31.40% in the same quarter last year. There is a high estimate of $44.5M for the next quarter, whereas the lowest estimate is $40.9M.
A total of 5 analysts have provided revenue estimates for XERS’s current fiscal year. The highest revenue estimate was $165M, while the lowest revenue estimate was $160.87M, resulting in an average revenue estimate of $162.62M. In the same quarter a year ago, actual revenue was $110.25M, up 47.50% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $188.01M in the next fiscal year. The high estimate is $203.6M and the low estimate is $184.02M. The average revenue growth estimate for next year is up 15.60% from the average revenue estimate for this year.
